Viewing Study NCT00098332

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:45 PM
Ignite Modification Date: 2026-04-14 @ 6:12 PM
Study NCT ID: NCT00098332
Status: COMPLETED
Last Update Posted: 2013-07-10
First Post: 2004-12-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Sponsor: BioCryst Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None recurrent cutaneous T-cell non-Hodgkin lymphoma View
None stage II cutaneous T-cell non-Hodgkin lymphoma View
None stage III cutaneous T-cell non-Hodgkin lymphoma View
None stage IV cutaneous T-cell non-Hodgkin lymphoma View
None recurrent mycosis fungoides/Sezary syndrome View
None stage II mycosis fungoides/Sezary syndrome View
None stage III mycosis fungoides/Sezary syndrome View
None stage IV mycosis fungoides/Sezary syndrome View